Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

M. Mascarella; T. Olonisakin; P. Rumde; V. Vendra; M. Nance; S. Kim; M. Kubik; S. Sridharan; R. Ferris; F. Moon; D. Clayburgh; J. Ohr; S. Joyce; M. Sen; J. Herman; J. Grandis; D. Zandberg; U. Duvvuri

doi:10.1016/S0959-8049(22)01141-8

Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

M. Mascarella
, T. Olonisakin
, P. Rumde
, V. Vendra
, M. Nance
, S. Kim
, M. Kubik
, S. Sridharan
, R. Ferris
, F. Moon
, D. Clayburgh
, J. Ohr
, S. Joyce
, M. Sen
, J. Herman
, J. Grandis
, D. Zandberg
, U. Duvvuri

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S128
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01141-8
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)01141-8

Cite this

Mascarella, M., Olonisakin, T., Rumde, P., Vendra, V., Nance, M., Kim, S., Kubik, M., Sridharan, S., Ferris, R., Moon, F., Clayburgh, D., Ohr, J., Joyce, S., Sen, M., Herman, J., Grandis, J., Zandberg, D., & Duvvuri, U. (2022). Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. European Journal of Cancer, 174, S128. https://doi.org/10.1016/S0959-8049(22)01141-8

Mascarella, M, Olonisakin, T, Rumde, P, Vendra, V, Nance, M, Kim, S, Kubik, M, Sridharan, S, Ferris, R, Moon, F, Clayburgh, D, Ohr, J, Joyce, S, Sen, M, Herman, J, Grandis, J, Zandberg, D & Duvvuri, U 2022, 'Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit', European Journal of Cancer, vol. 174, pp. S128. https://doi.org/10.1016/S0959-8049(22)01141-8

@article{65df0bc3a6ef4868b62e32d1e9bcee77,

title = "Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit",

author = "M. Mascarella and T. Olonisakin and P. Rumde and V. Vendra and M. Nance and S. Kim and M. Kubik and S. Sridharan and R. Ferris and F. Moon and D. Clayburgh and J. Ohr and S. Joyce and M. Sen and J. Herman and J. Grandis and D. Zandberg and U. Duvvuri",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01141-8",

language = "English (US)",

volume = "174",

pages = "S128",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

AU - Mascarella, M.

AU - Olonisakin, T.

AU - Rumde, P.

AU - Vendra, V.

AU - Nance, M.

AU - Kim, S.

AU - Kubik, M.

AU - Sridharan, S.

AU - Ferris, R.

AU - Moon, F.

AU - Clayburgh, D.

AU - Ohr, J.

AU - Joyce, S.

AU - Sen, M.

AU - Herman, J.

AU - Grandis, J.

AU - Zandberg, D.

AU - Duvvuri, U.

PY - 2022/10

Y1 - 2022/10

UR - https://www.scopus.com/pages/publications/85140474367

UR - https://www.scopus.com/pages/publications/85140474367#tab=citedBy

U2 - 10.1016/S0959-8049(22)01141-8

DO - 10.1016/S0959-8049(22)01141-8

M3 - Article

AN - SCOPUS:85140474367

SN - 0959-8049

VL - 174

SP - S128

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this